MEGGLE Excipients Partners with Brenntag Specialties
MEGGLE Excipients announces exclusive distribution agreement with Brenntag Specialties for pharmaceutical-grade lactose in Benelux and Nordics
MEGGLE Excipients is pleased to announce a strategic partnership with Brenntag Specialties, the global leading company in the distribution of chemicals and ingredients. This collaboration secures the exclusive distribution of MEGGLE’s premium pharmaceutical grade lactose excipients in the Benelux (Netherlands, Belgium and Luxembourg) and Nordic regions (Norway, Finland and Sweden).
A Broad Portfolio Tailored to Diverse Pharmaceutical Applications
From February 2025 onwards, customers in these regions will benefit from an extensive range of lactose-based excipients—over 30 products designed for applications such as:
- Tableting (granulation and direct compression)
- Powder Preparations
- Dry Powder Inhalation (DPI)
These high-quality excipients offer versatile and reliable solutions for pharmaceutical product development, ensuring precise adherence to specific formulation requirements and maximizing efficiency in manufacturing.
Strengthening the Pharmaceutical Supply Chain in Benelux and Nordics
Partnering with Brenntag Specialties ensures that MEGGLE’s excipients reach customers with reliability and speed. Brenntag’s robust logistics network, local market expertise, and commitment to quality make them the ideal partner for distributing pharmaceutical excipients in these regions.
Joakim Rehné, Brenntag Specialties President Pharma EMEA, states: “Customers are now supplied by us with lactose excipients of the highest quality, which are required to produce effective pharmaceuticals. The expanded product range strengthens our role as a key supplier to the global healthcare industry.”
Ruth Leinenbach, Director BU Excipients at MEGGLE, says: “This partnership enables us to make our excipients even more accessible to our customers. With Brenntag s’ extensive logistics network, proven expertise, and reliable infrastructure, we can ensure consistent and efficient delivery.”
Supporting Innovation in Pharmaceutical Manufacturing
Both MEGGLE and Brenntag are committed to supporting pharmaceutical innovation in Benelux and the Nordic countries, providing reliable excipient solutions for global healthcare. The collaboration aligns with MEGGLE’s mission to deliver superior excipients that empower customers to meet the highest quality standards in pharmaceutical manufacturing.
Learn More About Brenntag Specialties
Explore Brenntag Specialties:www.brenntag.com
About Brenntag:
Brenntag is the global market leader in chemicals and ingredients distribution. The company holds a central role in connecting customers and suppliers of the chemical industry. Headquartered in Essen, Germany, Brenntag has more than 17,700 employees worldwide and operates a network of about 600 sites in 72 countries. In 2023, Brenntag generated sales of 16.8 billion EUR. The two global divisions, Brenntag Essentials and Brenntag Specialties, provide a diversified and broad portfolio of industrial and specialty chemicals and ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, comprehensive regulatory know-how, and digital solutions for a wide range of industries. Brenntag pursues an ambitious sustainability agenda and is committed to sustainable solutions in its own sector and the industries served. Brenntag shares have been listed at the Frankfurt Stock Exchange since 2010, in the DAX since September 2021. In addition, the Brenntag SE shares are listed in the DAX 50 ESG and DAX ESG Target. For more information, visit www.brenntag.com.
About MEGGLE Excipients:
MEGGLE Group GmbH with its headquarter in the Bavarian city of Wasserburg (Germany), operates as a foundation for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 135 years in the dairy market. The Business Unit Excipients produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations, and exceptional product quality, MEGGLE plays a leading role in the global pharmaceutical excipients business. With production facilities in Wasserburg (Germany) and Le Sueur, Minnesota (USA), where the requirements of the North American market are served, MEGGLE is prepared to meet customer expectations worldwide. For more information, visit www.meggle-excipients.com